PCN122 Cost-Effectiveness of Brentuximab Vedotin for the Frontline Treatment of Peripheral T-Cell Lymphomas in Canada

Abstract

Authors

D. Zou J. Lee A. Kansal W. Ma M. Harris J. Lisano K. Fenton K. Yu-Isenberg

Full Text Cite This Article
Back to Volume 23, Supplemental S2
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×